ASCO Annual Meeting: Melanoma | Conference

Lifileucel Continues to Show Durable Responses in Advanced Melanoma
June 06, 2021

With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy

Lenvatinib-Pembrolizumab Combo Improves Outcomes in Certain Patients With Advanced Melanoma
June 06, 2021

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma efficacy results continue to show a durable response.

Nivolumab Monotherapy, With Ipilimumab Continuously Improves Outcomes in Advanced Melanoma
June 06, 2021

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.

Crossover to Pembrolizumab for Patients With Resected, Stage III Melanoma Yields Better Efficacy Vs Rechallenge
June 06, 2021

About 40% of patients who progressed on placebo following resection of melanoma experienced an objective response with crossover to pembrolizumab in the phase 3 EORTC 1325/KEYNOTE-054 trial.

Adding Lifileucel to Pembrolizumab for Immunotherapy-Naïve Melanoma Improved Responses
June 06, 2021

A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting.

Median PFS Extended in Advanced Melanoma Treated With Frontline Relatlimab/Nivolumab
May 19, 2021

Progression-free survival more than doubled when relatlimab was added to nivolumab to treated patients with previously untreated, unresectable or metastatic melanoma.

ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma
June 02, 2020

Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma.

Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission
June 20, 2019

Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.

Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients
June 19, 2019

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Dr. Hussein Tawbi on Efficacy and Safety Results From the CheckMate 204 Melanoma Trial
June 19, 2019

Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.